Answers are grounded in this paper and cite their sources.
FDA evaluates testosterone therapy for age-related hypogonadism, revealing insufficient evidence for use in older men.
Despite rampant direct-to-consumer ads regarding “low T” in older men, the Food and Drug Administration has concluded that the available evidence does not support an indication for testosterone therapy for “age-related hypogonadism.”
No takes yet. Share an insight, caveat, or question.
Nguyen et al. (2015) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: